Business Context and Reporting Period
This Form 8-K Current Report is filed by Inmune Bio, Inc. (Nasdaq: INMB) on December 5, 2025. The report discloses the termination of a material definitive agreement regarding the company's capital raising activities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific metrics related to the terminated sales agreement:
- Total Offering Capacity: Up to $75,000,000.
- Shares Issued Under Agreement: 1,353,469 shares of Common Stock.
- Net Proceeds Raised: Approximately $10.5 million.
- Termination Penalties: None.
Material Changes
The primary material change is the termination of the Amended and Restated At-The-Market Sales Agreement originally entered into on August 9, 2024, with RBC Capital Markets, LLC and BTIG, LLC. The Company notified the agents on December 5 and December 9, 2025, with the termination becoming effective on December 19, 2025. This action ends the Company's ability to sell shares through this specific "at-the-market" facility.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the cessation of the sales agreement. The Company explicitly states it is not subject to any termination penalties or other expenses related to this termination.
Investor Verification Checklist
- Verify the effective date of the termination (December 19, 2025) to confirm no further shares can be sold under the RBC/BTIG agreement.
- Confirm the total net proceeds of $10.5 million against the company's most recent cash balance in its latest 10-Q or 10-K.
- Assess the company's current liquidity position given the closure of this capital raising channel.
- Review the full text of the Sales Agreement (Exhibit 1.1) for any residual obligations not mentioned in the summary.